Literature DB >> 7710393

Comparison of the Baerveldt glaucoma implant with the double-plate Molteno drainage implant.

M F Smith1, J W Doyle, M B Sherwood.   

Abstract

OBJECTIVE: To compare the 350-mm2 Baerveldt implant with the double-plate Molteno implant in the treatment of eyes with complicated glaucoma.
DESIGN: Retrospective chart review of a consecutive series of drainage implants.
SETTING: University-based referral practice. PATIENTS: Thirty-four consecutive patients (37 eyes) undergoing glaucoma drainage device implantation because of uncontrolled, complicated glaucoma. INTERVENTION: Eighteen eyes underwent 350-mm2 Baerveldt implantation and 19 eyes underwent double-plate Molteno implantation. MAIN OUTCOME MEASURES: Intraocular pressure (IOP) control, visual acuity outcome, and complication rate.
RESULTS: Mean preoperative IOP was 30.2 mm Hg in the Baerveldt group, with an average of 2.7 antiglaucoma medications, and 28.4 mm Hg in the Molteno group, with an average of 2.4 antiglaucoma medications. With an average follow-up of 11.3 months (range, 5 to 16 months), mean IOP at the final visit was 13.1 mm Hg (range, 7 to 21 mm Hg) in the Baerveldt group, with an average of 1.3 medications, and 13.4 mm Hg (range, 8 to 25 mm Hg) in the Molteno group, with an average of 0.8 medications. Final IOP was between 7 and 19 mm Hg in 16 of 18 Baerveldt eyes and in 17 of 19 Molteno eyes. Visual acuity (when it could be checked) remained stable (+/- 2 Snellen lines) in 17 of 17 eyes in the Baerveldt group and in 17 of 19 eyes in the Molteno group. Complications in the Baerveldt group included two cases (11%) of flat anterior chamber after stent removal, one case (6%) of intermittently symptomatic diplopia, and one case (6%) of endophthalmitis. In the Molteno group there were two graft failures (11%) and one eye (5%) with loss of central field.
CONCLUSIONS: Both types of drainage implants provide excellent postoperative IOP control. Early stent removal should be avoided if possible in eyes with Baerveldt implants.

Entities:  

Mesh:

Year:  1995        PMID: 7710393     DOI: 10.1001/archopht.1995.01100040060027

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  9 in total

1.  Baerveldt implant in refractory glaucoma: long-term results and factors influencing outcome.

Authors:  S Roy; E Ravinet; A Mermoud
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

2.  Baerveldt® glaucoma implant surgery with the double scleral flap technique to prevent Hoffman elbow exposure.

Authors:  Naoki Tojo; Tomoko Ueda-Consolvo; Shuichiro Yanagisawa; Atsushi Hayashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-22       Impact factor: 3.117

3.  Five-year outcomes of eyes with glaucoma drainage device and penetrating keratoplasty.

Authors:  Robert M Knape; Tiffany N Szymarek; Sonal S Tuli; William T Driebe; Mark B Sherwood; Mary Fran Smith
Journal:  J Glaucoma       Date:  2012-12       Impact factor: 2.503

4.  Transvitreal endocyclophotocoagulation.

Authors:  J A Haller
Journal:  Trans Am Ophthalmol Soc       Date:  1996

5.  The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).

Authors:  Peter A Netland
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

6.  Tube Exposure Repair.

Authors:  Stirbu Oana; Jorge Vila
Journal:  J Curr Glaucoma Pract       Date:  2012-10-16

7.  Retrospective Comparison of Intermediate-term Efficacy of 350 mm2 Glaucoma Drainage Implants and Medium-sized 230-250 mm2 Implants.

Authors:  Alissa M Meyer; Cooper D Rodgers; Baiming Zou; Nicole C Rosenberg; Aaron D Webel; Mark B Sherwood
Journal:  J Curr Glaucoma Pract       Date:  2017-01-18

8.  Risk Factors for Failure in Double-Plate Tube Surgery for Refractory Glaucoma: 25 Years Surgical Experience.

Authors:  Susana Duch; Carlos A Arciniegas-Perasso; Stefania Piludu; Shirin Djavanmardi; Elena Milla
Journal:  Clin Ophthalmol       Date:  2021-02-09

9.  Evaluation of Bleb Fluid After Baerveldt Glaucoma Implantation Using Magnetic Resonance Imaging.

Authors:  Kentaro Iwasaki; Masayuki Kanamoto; Yuji Takihara; Shogo Arimura; Yoshihiro Takamura; Hirohiko Kimura; Masaru Inatani
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.